TABLE 5.
Effect of different studies (acute toxicity, subacute toxicity, and teratogenicity) on hematological parameters.
| Treatment (mg/kg) | WBC | RBC | Platelets | HB | Lym | Mid | Gra | MCH | MCHC | MCV | HCT |
|---|---|---|---|---|---|---|---|---|---|---|---|
| (×103/µl) | (×106/µl) | (×103/µl) | (g/dl) | (103/µl) | (103/µl) | (103/µl) | (pg) | (g/dl) | (fL) | (%) | |
| Control | 3.7 ± 0.1 | 5.9 ± 0.3 | 817 ± 0.1 | 12.0 ± 1.2 | 3.1 ± 1.4 | 0.4 ± 1.3 | 0.1 ± 0.02 | 20.3 ± 0.1 | 36.5 ± 0.9 | 55.4 ± 1.2 | 33.0 ± 3.2 |
| Acute oral toxicity | |||||||||||
| SF1 (2000) | 17.5 ± 1.2*** | 7.95 ± 3.2 | 474 ± 0.21^^^ | 14.2 ± 0.014 | 15.2 ± 1.08** | 0.4 ± 0.5 | 1.3 ± 0.32** | 18.10 ± 0.23 | 33.1 ± 0.85 | 54.7 ± 0.2 | 43.5 ± 1.3 |
| Subacute toxicity (male) | |||||||||||
| Control | 4.5 ± 0.1 | 6.1 ± 0.3 | 745 ± 0.14 | 12.6 ± 1.2 | 3.1 ± 1.4 | 0.9 ± 1.3 | 0.1 ± 0.02 | 20.30 ± 0.15 | 36.5 ± 0.96 | 55.4 ± 1.2 | 33.0 ± 3.2 |
| SF1 (5) | 4.6 ± 0.42 | 6.12 ± 0.38 | 459 ± 0.43^^^ | 12.9 ± 0.01 | 2.9 ± 1.0 | 0.7 ± 0.62 | 1.0 ± 0.01** | 21.0 ± 0.31 | 35.5 ± 0.78 | 59.1 ± 0.2 | 36.2 ± 1.3 |
| SF1 (10) | 4.2 ± 0.21 | 6.13 ± 0.16 | 615 ± 0.21 | 13.0 ± 0.12 | 3.0 ± 1.1 | 0.8 ± 0.7 | 0.4 ± 0.12 | 21.2 ± 0.25 | 36.2 ± 0.82 | 58.6 ± 0.1 | 35.6 ± 1.5 |
| SF1 (20) | 4.0 ± 0.43 | 4.94 ± 1.2 | 417 ± 0.12^^^ | 10.9 ± 0.11 | 85.8 ± 0.98*** | 6.3 ± 0.5*** | 7.9 ± 0.13*** | 20.1 ± 0.2 | 34.9 ± 0.84 | 57.7 ± 0.1 | 22.7 ± 1.1 |
| SF1 (40) | 5.0 ± 0.15 | 5.89 ± 1.1 | 350 ± 0.32^^^ | 10.6 ± 1.1 | 91.8 ± 1.02*** | 5.4 ± 0.6*** | 2.8 ± 0.1** | 18 ± 0.12 | 34.4 ± 0.79 | 52 ± 0.2 | 30.9 ± 2.4 |
| Subacute toxicity (female) | |||||||||||
| Control | 5.5 ± 0.12 | 6.0 ± 0.3 | 735 ± 0.1 | 11.2 ± 1.2 | 2.9 ± 1.4 | 0.6 ± 1.3 | 0.1 ± 0.02 | 20.3 ± 0.1 | 36.5 ± 0.9 | 55.4 ± 1.2 | 33.0 ± 3.2 |
| SF1 (5) | 10.8 ± 0.2*** | 5.92 ± 1.1 | 221 ± 0.2^^^ | 12.7 ± 0.1 | 9.6 ± 1.0* | 0.8 ± 0.3 | 0.4 ± 0.0 | 21.6 ± 0.1 | 34.1 ± 0.8 | 63.3 ± 0.1 | 37.5 ± 1.2 |
| SF1 (10) | 10.2 ± 0.1*** | 5.11 ± 1.2 | 750 ± 0.3 | 11.2 ± 0.1 | 9.0 ± 1.1* | 0.8 ± 0.5 | 0.4 ± 0.2 | 22 ± 0.2 | 36.1 ± 0.8 | 61.0 ± 0.2 | 31.2 ± 1.5 |
| SF1 (20) | 9.0 ± 0.3*** | 6.53 ± 2.1 | 188 ± 0.1^^^ | 13.5 ± 0.1 | 7.3 ± 1.0* | 1.1 ± 0.6 | 0.6 ± 0.6 | 20.6 ± 0.2 | 35.9 ± 0.9 | 57.5 ± 0.1 | 37.5 ± 1.1 |
| SF1 (40) | 11.8 ± 0.2*** | 6.55 ± 1.3 | 606 ± 0.3 | 12.9 ± 0.1 | 10.1 ± 1.1* | 1.1 ± 0.6 | 0.6 ± 0.1 | 19.9 ± 0.2 | 35.1 ± 0.7 | 56.7 ± 0.2 | 37.1 ± 1.2 |
| Teratogenicity | |||||||||||
| Control | 5.7 ± 0.1 | 5.95 ± 0.3 | 821 ± 0.1 | 11.5 ± 1.2 | 6.1 ± 1.4 | 0.5 ± 1.3 | 0.1 ± 0.02 | 20.3 ± 0.1 | 36.5 ± 0.9 | 55.4 ± 1.2 | 33.0 ± 3.2 |
| SF1 (40) | 12.8 ± 0.2*** | 5.65 ± 1.1 | 1,000 ± 0.2*** | 11.0 ± 0.14 | 10.9 ± 1.1* | 1.5 ± 0.5 | 0.4 ± 0.1 | 19.6 ± 0.2 | 33.5 ± 0.8 | 58.6 ± 0.2 | 33.1 ± 1.2 |
Data represented as mean ± SEM; n = 5 for acute toxicity and n = 10 for teratogenicity and subacute toxicity studies. *p < 0.05, **p < 0.01, ***p < 0.001 were increased levels of significance while ^^^ p < 0.001 was a decreased level of significance in comparison to the control.